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Abstract
Signs and symptoms of arrhythmias or conduction defects are frequently reported in patients with SSc.
These rhythm disorders may have several origins (i.e. related to primary heart involvement, pericardial
disease, valvular regurgitation or pulmonary arterial hypertension) and may negatively affect the overall
prognosis of these patients. It is therefore important to identify patients at high risk for cardiac arrhythmias
with a complete cardiological evaluation and to identify the underlying heart disease, including SSc-related
myocardial involvement. In addition, some therapeutic options in SSc patients may differ from those
recommended in other populations.
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Introduction
SSc is a systemic disease with multiple organ involve-
ment. Although only relatively recently recognized, the
heart is frequently affected and the presence of cardiac
involvement portends a poor outcome for the patient
[1, 2]. Cardiac manifestations of SSc can affect all struc-
tures of the heart and may result in pericardial disease,
arrhythmias, conduction system abnormalities, direct
myocardial disease such as myositis, cardiac failure, car-
diac fibrosis, coronary artery diseases and, rarely, primary
valvular involvement. Primary myocardial manifestations
(without systemic or pulmonary hypertension and without
significant pulmonary or renal disease) result from the
underlying vascular lesions and fibrosis that impair micro-
circulation and myocardial function, respectively [3].
Several reports have described electrocardiographic
abnormalities in SSc. Whether electrocardiographic
abnormalities are a consequence of myocardial involve-
ment in SSc, transient oxygen-supply imbalance or other
mechanisms remains uncertain [46].
An abnormal ECG is present in 2575% of patients with
SSc and is considered an independent predictor of mor-
tality [7, 8]. Arrhythmias may be associated with poor out-
come and represent 6% of the overall causes of death in
the large European League Against Rheumatism (EULAR)
Scleroderma Trials and Research (EUSTAR) database [9].
Out of 128 SSc-related deaths, 33 (26%) were of cardiac
origin, with about half of them due to malignant ar-
rhythmias [9]. One report from the Genetics Versus
Environment In Scleroderma Outcome Study (GENISOS)
cohort, which included 250 patients with 3 years of dis-
ease duration, showed a total of 52 deaths, with 29 deaths
(55.8%) related to SSc. In the final multivariable Cox
model that included non-genetic candidate risk factors
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simultaneously in the analysis, only seven variables were
independent predictors of mortality: BMI, age, forced
vital capacity, blood pressure, pulmonary fibrosis, anti-
centromere antibody and cardiac arrhythmias [hazard
ratio (HR) 2.18 (95% CI 1.05, 4.50); P= 0.035 for cardiac
arrhythmias] [10].
Arrhythmias
In a study by Ferri et al. [11], resting ECG showed one or
more abnormal features in 22/53 (42%) SSc patients.
Rhythm disturbances were demonstrated in 30% of pa-
tients, but when 24-h Holter ECG monitoring was per-
formed, supraventricular arrhythmias were documented
in 66% of SSc patients and ventricular arrhythmias were
found in 90%, with multiform ventricular premature beats
in 40%, pairs of runs of ventricular tachycardia in 28%,
and one or more runs of ventricular tachycardia in 13%.
The prevalence and severity of ventricular arrhythmias did
not correlate with clinical variants or with other clinical
symptoms and signs of the disease. Abnormal ventricular
arrhythmias were more likely in patients with echocardio-
graphic abnormalities, although ECG results were normal
in about half of the patients who had ventricular arrhyth-
mias. It is generally acknowledged that ventricular arrhyth-
mias, particularly multiform and/or repetitive ventricular
premature beats, have a poor prognosis when associated
with impaired myocardial function. The high incidence of
arrhythmias in this study may be explained by both the
high sensitivity and lower specificity of Holter ECG [11].
A multicentre ambulatory ECG study in 183 SSc patients
showed ventricular ectopy in 67% of patients, and this ab-
normality correlated with total mortality and sudden death.
Episodes of ventricular tachycardia and supraventricular
tachycardia were also observed in 7% and 21% of pa-
tients, respectively [8]. Despite the very frequent occur-
rence of ventricular arrhythmias, sudden cardiac death is
not very common in SSc. A large observational study re-
ported sudden cardiac death in 18 (5%) of 391 deaths
occurring in 1258 SSc patients, and severe cardiac arrhyth-
mias with a poor prognosis were significantly more frequent
in patients with concomitant skeletal and cardiac muscle
involvement [12]. In a meta-analysis evaluating 436 con-
secutive cases, Follansbee et al. [6] reported the presence
of an abnormal ECG in 46% of patients. Focusing the ana-
lysis on 100 selected SSc subjects presenting with evident
cardiac abnormalities as assessed by a detailed cardiopul-
monary evaluation or who died of more advanced disease,
an abnormal ECG was found in 95% of cases.
Many electrophysiological abnormalities can be re-
vealed only after careful and specific cardiac workup.
Rokas et al. [13] assessed SSc patients without evidence
of myocardial involvement and arrhythmias by rest and
24-h Holter ECG, echocardiography and radionuclide ven-
triculography. They found one or more of significant
supraventricular or ventricular tachyarrhythmia, sinus
node dysfunction and atrioventricular conduction delay
in 57% of the patients. The marked atrial conduction
delay probably occurs because of depression of the con-
duction velocity of abnormal atrial fibres, changes in the
resting membrane potential, the action potential ampli-
tude or the maximal velocity of the action potential up-
stroke, which are all associated with depressed
conduction velocity and abnormal excitability. This high
prevalence in the absence of any clinical symptoms or
signs on standard ECG highlights the need for complete
investigation, even at an early stage of the disease, long
before the clinical manifestations of scleroderma heart
disease (SHD) have appeared.
Other parameters that can be evaluated in SSc patients
during 24-h Holter ECG monitoring are heart rate variabil-
ity (HRV) and heart rate turbulence (HRT). HRV is a meas-
ure of cardiovascular autonomic activity and its decrease
after myocardial infarction is thought to be associated
with increased cardiovascular risk. HRT describes a fluc-
tuation during sinus cycle length that occurs after a ven-
tricular premature beat. It is controlled by the autonomic
nervous system and reflects baroreflex sensitivity. As
observed in post-infarction studies, HRT impairment is
an independent risk factor for malignant ventricular ar-
rhythmia and sudden cardiac death. Bielous-Wilk et al.
[14] analysed 27 SSc patients without clinically evident
heart disease and observed a significantly greater
number of premature contractions (supraventricular and
ventricular), indicating a possible arrhythmogenic sub-
strate within myocardium. Four patients also manifested
supraventricular tachycardia. Several studies demon-
strated impairment of HRV in time and frequency domains
as well as HRT, confirming that patients with SSc develop
cardiac autonomic nervous system dysfunction [14, 15].
Moreover, HRT seems to be a potential useful tool for the
identification of patients at risk for ventricular arrhythmia,
and might be considered an independent risk factor for
mortality in SSc, although further studies are warranted
before recommending routine HRT measurement in all
SSc patients [15].
Conduction and other frequent ECG
abnormalities
An interesting autopsy study in 35 SSc patients showed
focal fibrotic changes in the specialized conduction tissue
of the heart, but they were not unequivocally related to the
presence of SSc-type myocardial fibrosis. In fact, they
were generally present with equal frequency in the
group of patients with and without SHD. Moreover, they
are infrequently of clinical significance. Although conduc-
tion abnormalities were more common in SSc patients
with myocardial disease, specific conduction system dis-
ease was not the cause of death in most patients. In fact,
the conduction system appeared to be relatively spared
from the myocardial changes of SSc, and the high inci-
dence of conduction disturbances may be a consequence
of, rather than caused by, specific damage to the proximal
portion of the specialized conduction tissue [16]. In a pro-
spective study, 16 of 50 SSc patients (32%) had resting
ECG conduction abnormalities. The most common alter-
ation was left bundle branch block (16%), followed by
first-degree atrioventricular block (8%), while second- and
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third-degree atrioventricular block were infrequent (<2%)
[7]. In a large study by Ferri et al. [11], resting ECG demon-
strated conduction defects in 19% and ST-T changes in
5%. Moreover, this prevalence increased to 34% for ST-T
changes and to 33% for A-V block (mostly first- or
second-degree atrioventricular block) when 24-h Holter
monitoring was performed. Other authors showed a simi-
lar prevalence of conduction disturbances. In addition,
QTc prolongation, which can lead to life-threatening
tachyarrhythmias, has also been reported [17].
An electrocardiographic study performed in 102 SSc
patients investigated the functional correlates of the
abnormalities found in 48 patients in whom detailed car-
diac physiological data were available. About 50% had
normal findings on ECG; the most common ECG abnor-
mality was isolated nonspecific ST-T wave changes
(14%), and conduction abnormalities were common
(17%). Functional correlations showed that 5/48 (10%)
had septal infarction pattern and 10/48 (21%) had ven-
tricular conduction defects. Four of the five (80%) patients
with septal infarction pattern had septal or anteroseptal
thallium perfusion defects; the fifth had an inferoapical
perfusion defect. In four of the five cases, the perfusion
defects were fixed, suggesting underlying myocardial fi-
brosis. Six of the 10 (60%) patients with ventricular con-
duction abnormalities also had septal or anteroseptal
thallium perfusion abnormalities. All six had fixed perfu-
sion defects, and four of the six also had redistribution
defects. Therefore 10/15 (67%) SSc patients with one of
these ECG abnormalities had a septal or anteroseptal
thallium perfusion defect compared with 6/33 (18%) of
the remainder (P< 0.005). Three patients with septal
infarction pattern and three with ventricular conduction
defects underwent coronary angiography. All had septal
thallium perfusion abnormalities, but all six had normal
coronary angiography results. Septal infarction pattern
seemed to be an unrecognized ECG abnormality asso-
ciated with SSc, related to abnormal perfusion in the
septum and anteroseptal wall in the absence of extra-
mural coronary artery disease. These fixed defects sug-
gested underlying myocardial fibrosis, consistent with the
hypothesis that septal infarction pattern or ventricular
conduction abnormalities identify more advanced myo-
cardial involvement in patients with SSc [6].
Pathophysiological alterations
Cardiac involvement is the result of microvascular alter-
ations, collagen overproduction by altered fibroblasts with
extracellular matrix deposition and complex immune
system dysregulation. A variable combination of
the above mechanisms leads to ischaemic, fibrotic and
inflammatory lesions involving all cardiac structures,
including the cardiac conduction system. Histology exam-
inations revealed the presence of patchy myocardial fibro-
sis that could involve the conduction system in SSc
[7, 16]. However, it is unclear whether fibrosis is the only
underlying pathology responsible for these conduction
defects. Ridolfi et al. [16] concluded that focal fibrotic
changes may be present within the sinoatrial node and
proximal portion of the bundle branch system, but they
are unrelated to the presence of SHD, as it was found
with equal frequency in the group of patients without
SHD. The majority of conduction defects appear to be a
consequence of damaged myocardium rather than spe-
cific damage to the proximal portion of the specialized
conduction tissue. The conduction tissue of the heart
was relatively spared from injury by the SSc disease pro-
cess when compared with the changes seen within the
contracting myocardium. Moreover, compared with the
contractile myocardium, specialized conduction tissue
appears to be less sensitive to ischaemic injury, arguing
against the so-called intra-myocardial RP, which suggests
that focal contraction band necrosis is caused by inter-
mittent spasm before evolving to focal replacement fibro-
sis. This may explain the relatively rare involvement of the
conduction system of the heart by the SSc process [16].
In contrast, other authors found an association between
atrioventricular node fibrosis and first-degree atrioven-
tricular block [7]. Interestingly, a recent cardiac MRI
study on SSc patients reported a correlation between
the presence of cardiac arrhythmias, conduction disturb-
ances and myocardial fibrosis [18]. Analysis of Holter
monitoring data showed that 19/36 patients (53%) had
abnormal study results. Among the 19 patients, 12
(63%) had premature ventricular contractions, 2 (10.5%)
had supraventricular tachycardia, 3 (16%) had premature
atrial contractions, 2 (10.5%) had atrial fibrillation and 2
(10.5%) had non-sustained ventricular tachycardia. Two
additional patients (10.5%) had right bundle branch
block and one patient (5%) had left bundle branch
block. Compared with the 17 patients with normal Holter
study results, patients with abnormal results were more
likely to have pulmonary hypertension by Doppler echo-
cardiography, a decreased left ventricular (LV) ejection
fraction, an increased right ventricular (RV) diameter and
a greater number of enhancing myocardial segments at
delayed enhanced cardiac MRI study [18].
Studies that correlate autoptic findings with cardiac
MRI abnormalities are not presently available, but we
can make some indirect correlations. Cardiac MRI en-
ables analysis of the different patterns of heart involve-
ment in SSc by differentiating morphological, functional,
perfusion and delayed contrast enhancement abnormal-
ities. The high frequency of heart abnormalities observed
on cardiac MRI is consistent with necropsy studies, which
have shown that approximately 80% of patients with SSc
have histological lesions of heart involvement [19].
In the large EUSTAR database, the prevalence of LV
dysfunction is 5.4%, and conduction abnormalities on
ECG have been observed in 33% of patients with de-
pressed LV ejection fraction [20].
The frequent ECG abnormalities observed in these stu-
dies indicate the presence of alterations in the cardiac
centres of impulse formation and conduction, and suggest
that electrical instability of the heart is an integral clinical
feature of SHD [7].
A recent study evaluated myocardial dysfunction using
novel speckle-tracking strain. Of a total of 104 patients
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with SSc [53 dcSSc; mean age (S.D.) 54 (12) years, 77%
female], 28 patients had abnormal findings (ventricular
tachycardia or ventricular ectopics> 100/day) on ECG
Holter monitoring. Compared with SSc patients with
normal results on ECG Holter monitoring, SSc patients
with abnormal results showed impaired global longitudinal
strains [mean 18.5% (S.D. 1.5) vs 17.1% (2.1); P< 0.01]
and circumferential strains [mean 18.7% (S.D. 2.0) vs
17.3% (2.5); P= 0.01], and each strain measure was in-
dependently associated with abnormal Holter findings.
The predictive value of such findings remains to be
established but it strengthens the proposed relation-
ship between myocardial impairment and rhythm disturb-
ances [21].
In conclusion, fibrosis, dynamic vasospasm and inflam-
mation of the heart and small heart nerves are possible
causal factors. Sympathetic autonomic nervous system
activation resulting from even subclinical heart failure,
and a subsequent recruitment of baroreceptors, may
also be important causal factors and may contribute to
the severity of SHD [12].
Diagnostic workup
The cardiac workup in patients with SSc includes routine
and second-level investigations, both for electrical
assessment and heart evaluation, as summarized in
Table 1. Standard 12-lead ECG as well as Doppler echo-
cardiography should be performed routinely in all SSc pa-
tients, even if the patient is asymptomatic. If the patient
complains of palpitations, syncope or dizziness, the next
steps must include exercise testing, upright tilt-table test-
ing and 24-h Holter monitoring.
When significant changes are detected in the conduc-
tion and rhythm systems, careful investigations for heart
disease must be performed. First, classic cardiovascular
risk factors should be assessed together with any poten-
tial signs or symptoms of ischaemic heart disease. If SHD
is suspected, echocardiography should be performed,
when possible, by pulsed Doppler. In addition, cardiac
MRI to evaluate tissue damage may be considered, par-
ticularly if there are any signs of myositis, in order to rule
out myocarditis, which demands specific management
[22].
Although not yet endorsed by any guideline, given the
high prevalence and the prognostic significance of ar-
rhythmias and conduction defects, we believe that 24-h
Holter monitoring should be considered as part of routine
evaluation in SSc patients, even if asymptomatic, every
12 years. A validation study to determine the possible
impact of such an attitude and the ideal time interval is
warranted. The patient should also be questioned about
the presence of systemic illnesses that can be associated
with arrhythmias such as chronic obstructive pulmonary
disease, hyperthyroidism, pericarditis and congestive
heart failure. Moreover, in SSc, several complications
might favour arrhythmia, such as life-threatening infec-
tions related to severe motility disorders of the intestine
or electrolyte imbalance because of gut or kidney involve-
ment [23]. Measurement of HRT and HRV should be con-
sidered in selected patients after detailed clinical,
echocardiographic and standard ECG and Holter monitor-
ing evaluations. Invasive electrophysiological studies are
indicated in patients who have atrioventricular block,
intraventricular conduction disturbance, sinus node dys-
function, tachycardia and unexplained syncope or palpi-
tations [24].
Treatment
Since different classes of anti-arrhythmics are available,
and SSc patients may have multiple organs involved and
take concomitant drugs, the choice of treatment must be
personalized to the individual patient. Conduction
abnormalities and arrhythmias may be an adverse effect
of some drugs commonly used by such patients.
Corticosteroids, in particular, high i.v. doses of methyl-
prednisolone, although rarely used in SSc, are associated
with tachyarrhythmias. MTX may rarely induce right
bundle branch block and ventricular arrhythmias. HCQ is
safer than chloroquine in terms of heart conduction dis-
orders. Some epidemiological studies have reported the
relation between domperidone and serious ventricular
arrhythmia or sudden cardiac death. Because of the
TABLE 1 Cardiac diagnostic workup in patients with SSc for investigations of electrical disturbances
Clinical manifestation Electrical assessment Heart assessment
Fatigue
Palpitations
Syncope, fall
Dizziness
Routine:
CV risk factor assessment
Standard 12-lead ECG
24-h Holter monitoring
Second level:
Exercise testing
Upright tilt-table testing
Invasive electrophysiological studies
Measurement of HRT and HRV
Routine:
Doppler echocardiography
Tissue Doppler echocardiography
Natriuretic peptides
Second level:
Coronary angiography
Right heart catheterization
Cardiac MRI
CV: cardiovascular; ECG: electrocardiogram; HRT: heart rate variability; HRV: heart rate turbulence.
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frequency of gastrointestinal (GI) involvement and the
widespread use of prokinetic drugs in SSc, clinicians
must be aware of such risk. Moreover, potential harmful
effects in SSc patients regarding other organ involvement
might be a matter for future research [25, 26].
As no randomized controlled trials have been per-
formed specifically in SSc patients, the choice of therapy
should be similar to that of patients without SSc, but phys-
icians should keep the following in mind:
(i) The negative effect of b-blockers on RP, except for
the new molecules, such as metoprolol, that seem
to reduce symptoms in patients suffering from RP
when co-administered with calcium channel block-
ers [27].
(ii) The beneficial effect on RP offered by calcium
channel blockers as well as their possible prevent-
ive effect on LV ejection fraction deterioration.
Nifedipine has been associated with tachycardia,
possibly through a sympathetic reflex. However,
most of these occurred when nifedipine was used
as a tocolytic at high dosage for preterm labour.
Previous reports have shown that an increase in
heart rate is of very limited impact except for pa-
tients with advanced coronary artery disease, rarely
documented in SSc. In addition, an improvement in
LV ejection fraction, LV contractility, LV filling and
RV contractility after calcium channel blocker use in
SSc has also been reported [28, 29]. Thus verap-
amil-like calcium channel blockers might be recom-
mended in the treatment of atrial or intranodal
tachycardia, although their efficacy is somewhat
limited.
(iii) The prevalence of myocardial ischaemia and, as a
consequence, the possible detrimental effect of
class I anti-arrhythmic drugs.
(iv) Amiodarone is the most effective antiarrhythmic
drug. Side effects include immuno-allergic pneumo-
nia. There is no evidence that pre-existing pulmon-
ary fibrosis increases the risk of immuno-allergic
pneumonia, but it will worsen its consequences.
Implantable cardioverter defibrillators (ICDs), which moni-
tor the cardiac rhythm and can deliver competing pacing
stimuli and low- and high-energy shocks, have been used
effectively in selected patients to prevent malignant ven-
tricular arrhythmias. There is no specific recommendation
in SSc patients; an ICD should be considered in patients
at high risk of sudden death, in secondary prevention and
in primary prevention for patients with an LV ejection frac-
tion <30% (35% if ischaemic) and with proven symptom-
atic ventricular tachyarrhythmia. One should keep in mind
that ICD should be considered only in patients without
advanced organ failure other than the heart. An ICD was
implanted in 10 patients with SSc who had cardiac in-
volvement, mainly related to diastolic dysfunction. After
36 months, analysis of the device showed several epi-
sodes of ventricular tachycardia in three patients, which
were promptly reverted by electrical shock delivery [30].
Catheter ablation therapy allows the destruction of a
delimited atrial/ventricular zone. During the last decade,
the risk of side effects has been reduced and its indication
has been defined. Thus it should be considered as
first-line therapy in patients with recurrent re-entrant
tachycardia or atrial flutter, in patients with symptomatic,
sustained, monomorphic ventricular tachycardia resistant
or intolerant to pharmacological treatment and in patients
with recurrent symptomatic atrial fibrillation despite anti-
arrhythmic drugs.
Pacemaker implantation is the treatment of choice
for complete heart block and other serious bradyarrhyth-
mias [17].
Conclusion
Arrhythmias and conduction defects are important and
frequent manifestations of cardiac involvement in patients
with SSc. These abnormalities may be mild, but can also
lead to a fatal outcome. The underlying arrhythmogenic
mechanisms are not well understood, but myocardial
damage and fibrosis seem to be the most important fac-
tors. Whether or not an appropriate treatment might affect
the disease process in the myocardium remains to be
confirmed. However, early recognition of life-threatening
ventricular arrhythmias may be crucial in improving the
overall prognosis of SSc patients.
Rheumatology key messages
. Arrhythmias and conduction abnormalities worsen
the overall prognosis of SSc.
. Patchy myocardial fibrosis could involve the con-
duction system in SSc.
. Anti-arrhythmic treatment must be adapted to the
individual SSc patient.
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